Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ironwood Pharmaceuti (IRWD)

Ironwood Pharmaceuti (IRWD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ironwood Pharmaceuti 100 SUMMER STREET SUITE 2300 BOSTON MA 02110 USA

www.ironwoodpharma.com Employees: 267 P: 617-621-7722 F: 617-494-0480

Description:

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.

Key Statistics

Overview:

Market Capitalization, $K 563,299
Enterprise Value, $K 970,709
Shares Outstanding, K 160,028
Annual Sales, $ 442,740 K
Annual Net Income, $ -1,002 M
Last Quarter Sales, $ 91,590 K
Last Quarter Net Income, $ 3,650 K
EBIT, $ 99,230 K
EBITDA, $ 100,810 K
60-Month Beta 0.47
% of Insider Shareholders 12.90%
Float, K 139,384
% Float 87.10%
Short Volume Ratio 0.73

Growth:

1-Year Return -64.35%
3-Year Return -68.46%
5-Year Return -70.72%
5-Year Revenue Growth 27.72%
5-Year Earnings Growth -560.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.02 on 11/07/24
Next Earnings Date N/A
Earnings Per Share ttm 0.00
EPS Growth vs. Prev Qtr -7.41%
EPS Growth vs. Prev Year -83.33%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

IRWD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 38.10
Price/Earnings to Growth N/A
Return-on-Equity % -0.96%
Return-on-Assets % 0.74%
Profit Margin % -226.37%
Debt/Equity -1.28
Price/Sales 1.38
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.95
Interest Coverage -42.83
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar